Glucagon-like peptide-1 and the entero-insular axis in obese hyperglycaemic (ob/ob) mice.
The intestines of obese hyperglycaemic (ob/ob) mice contain greatly increased amounts of glucagon-like immunoreactive peptides. To investigate their role in the increased activity of the entero-insular axis of these mice, the insulin-releasing effect of glucagon-like peptide-1 (GLP-1) was examined in 24 hour fasted 12-15 weeks old ob/ob mice under conditions of basal and elevated glycaemia. Compared with glucagon (100 micrograms/kg ip), which produce an approximately 3-fold increase in basal plasma glucose and insulin concentrations, GLP-1 (100 micrograms/kg ip) produce a very small (less than 1 fold) increase in plasma insulin, with no significant change in plasma glucose. The insulin-releasing effect of glucagon, but not GLP-1 was increased by administration in combination with glucose (2 g/kg ip). The results indicate that GLP-1, which exhibits considerable sequence homology with glucagon, exerts only a weak insulin-releasing effect without a significant hyperglycaemic effect in ob/ob mice. Thus GLP-1 is unlikely to be an important endocrine component of the two over-active entero-insular axis in ob/ob mice.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D005934:Glucagon / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007422:Intestines / Q000032:analysis*; D007515:Islets of Langerhans / Q000187:drug effects*; D051379:Mice; D008820:Mice, Obese; D010455:Peptides / Q000032:analysis / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D010455:Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon